To demonstrate the role of RAD18 in TMZ-resistance in patients suffering from glioma, the subtype-specific RAD18 mRNA expression pattern of glioma samples grade I-IV was investigated using the Gene Expression database of Normal and Tumor tissues 2 (GENT2) [60] on multiple microarray datasets (Table S5 and Fig. 6F). This evidence concerns the gene RAD18 and central nervous system cancer.